Correlation between Concentrations of Fecal Calprotectin and Outcomes of Patients with Ulcerative Colitis in a Phase 2 Trial

Gastroenterology

Volumn 150, Issue 1, 2016, Pages 96-102

  Sandborn, William J ^a   Panés, Julian ^b   Zhang, Haiying ^c   Yu, Dahong ^c   Niezychowski, Wojciech ^c   Su, Chinyu ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b HOSPITAL CLÍNIC   (Spain)

^c PFIZER INC   (United States)

Author keywords

Biomarkers; Endoscopy; Mayo Score; Tofacitinib

Indexed keywords

BIOLOGICAL MARKER; CALGRANULIN; PLACEBO; TOFACITINIB; PIPERIDINE DERIVATIVE; PYRIMIDINE DERIVATIVE; PYRROLE DERIVATIVE;

ADULT; ARTICLE; COMPARATIVE STUDY; CORRELATIONAL STUDY; DISEASE ACTIVITY; DISEASE DURATION; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; ENDOSCOPY; FECES LEVEL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; REMISSION; TREATMENT DURATION; TREATMENT RESPONSE; ULCERATIVE COLITIS; AREA UNDER THE CURVE; CHEMISTRY; CLINICAL TRIAL; COLITIS, ULCERATIVE; COLONOSCOPY; CONFIDENCE INTERVAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG ADMINISTRATION; FECES; FOLLOW UP; METABOLISM; MIDDLE AGED; ORAL DRUG ADMINISTRATION; PROCEDURES; RANDOMIZED CONTROLLED TRIAL; RECEIVER OPERATING CHARACTERISTIC; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; YOUNG ADULT;

ADMINISTRATION, ORAL; ADULT; AREA UNDER CURVE; BIOMARKERS; COLITIS, ULCERATIVE; COLONOSCOPY; CONFIDENCE INTERVALS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FECES; FEMALE; FOLLOW-UP STUDIES; HUMANS; LEUKOCYTE L1 ANTIGEN COMPLEX; MALE; MIDDLE AGED; PIPERIDINES; PYRIMIDINES; PYRROLES; ROC CURVE; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84952716488     PISSN: 00165085     EISSN: 15280012     Source Type: Journal    
DOI: 10.1053/j.gastro.2015.09.001     Document Type: Article

References (38)

1. E. Langholz, P. Munkholm, M. Davidsen, and et al. Course of ulcerative colitis: analysis of changes in disease activity over years Gastroenterology 107 1994 3 11
2. G. D'Haens, W.J. Sandborn, B.G. Feagan, and et al. A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis Gastroenterology 132 2007 763 786
3. K.F. Froslie, J. Jahnsen, B.A. Moum, and et al. Mucosal healing in inflammatory bowel disease: results from a Norwegian population-based cohort Gastroenterology 133 2007 412 422
4. J.F. Colombel, P. Rutgeerts, W. Reinisch, and et al. Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis Gastroenterology 141 2011 1194 1201
5. L. Peyrin-Biroulet, M. Ferrante, F. Magro, and et al. Results from the 2nd Scientific Workshop of the ECCO. I: impact of mucosal healing on the course of inflammatory bowel disease J Crohns Colitis 5 2011 477 483
6. A. Armuzzi, G. Van Assche, W. Reinisch, and et al. Results of the 2nd scientific workshop of the ECCO (IV): therapeutic strategies to enhance intestinal healing in inflammatory bowel disease J Crohns Colitis 6 2012 492 502
7. D. Laharie, J. Filippi, X. Roblin, and et al. Impact of mucosal healing on long-term outcomes in ulcerative colitis treated with infliximab: a multicenter experience Aliment Pharmacol Ther 37 2013 998 1004
8. S.P. Travis, D. Schnell, P. Krzeski, and et al. Developing an instrument to assess the endoscopic severity of ulcerative colitis: the Ulcerative Colitis Endoscopic Index of Severity (UCEIS) Gut 61 2012 535 542
9. B.G. Feagan, W.J. Sandborn, G. D'Haens, and et al. The role of centralized reading of endoscopy in a randomized controlled trial of mesalamine for ulcerative colitis Gastroenterology 145 2013 149 157
10. S. Vermeire, S. O'Byrne, M. Keir, and et al. Etrolizumab as induction therapy for ulcerative colitis: a randomised, controlled, phase 2 trial Lancet 384 2014 309 318
11. A.G. Roseth, M.K. Fagerhol, E. Aadland, and et al. Assessment of the neutrophil dominating protein calprotectin in feces. A methodologic study Scand J Gastroenterol 27 1992 793 798
12. A.G. Roseth, P.N. Schmidt, and M.K. Fagerhol Correlation between faecal excretion of indium-111-labelled granulocytes and calprotectin, a granulocyte marker protein, in patients with inflammatory bowel disease Scand J Gastroenterol 34 1999 50 54
13. F. Costa, M.G. Mumolo, L. Ceccarelli, and et al. Calprotectin is a stronger predictive marker of relapse in ulcerative colitis than in Crohn's disease Gut 54 2005 364 368
14. J.A. Tibble, G. Sigthorsson, S. Bridger, and et al. Surrogate markers of intestinal inflammation are predictive of relapse in patients with inflammatory bowel disease Gastroenterology 119 2000 15 22
15. R.F. van Vollenhoven, R. Fleischmann, S. Cohen, and et al. Tofacitinib or adalimumab versus placebo in rheumatoid arthritis N Engl J Med 367 2012 508 519
16. R. Fleischmann, J. Kremer, J. Cush, and et al. Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis N Engl J Med 367 2012 495 507
17. G.R. Burmester, R. Blanco, C. Charles-Schoeman, and et al. Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial Lancet 381 2013 451 460
18. D. van der Heijde, Y. Tanaka, R. Fleischmann, and et al. Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: twelve-month data from a twenty-four-month phase III randomized radiographic study Arthritis Rheum 65 2013 559 570
19. J. Kremer, Z.G. Li, S. Hall, and et al. Tofacitinib in combination with nonbiologic DMARDs in patients with active rheumatoid arthritis: a randomized trial Ann Intern Med 159 2013 253 261
20. E.B. Lee, R. Fleischmann, S. Hall, and et al. Tofacitinib versus methotrexate in rheumatoid arthritis N Engl J Med 370 2014 2377 2386
21. K.A. Papp, A. Menter, B. Strober, and et al. Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, in the treatment of psoriasis: a phase 2b randomized placebo-controlled dose-ranging study Br J Dermatol 167 2012 668 677
22. W.J. Sandborn, S. Ghosh, J. Panes, and et al. A phase 2 study of tofacitinib, an oral Janus kinase inhibitor, in patients with Crohn's disease Clin Gastroenterol Hepatol 12 2014 1485 1493
23. W.J. Sandborn, S. Ghosh, J. Panes, and et al. Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis N Engl J Med 367 2012 616 624
24. E. Husebye, H. Ton, and B. Johne Biological variability of fecal calprotectin in patients referred for colonoscopy without colonic inflammation or neoplasm Am J Gastroenterol 96 2001 2683 2687
25. J. Tibble, K. Teahon, B. Thjodleifsson, and et al. A simple method for assessing intestinal inflammation in Crohn's disease Gut 47 2000 506 513
26. B. Moum, J. Jahnsen, and T. Bernklev Fecal calprotectin variability in Crohn's disease Inflamm Bowel Dis 16 2010 1091 1092
27. D. Turner, S.T. Leach, D. Mack, and et al. Faecal calprotectin, lactoferrin, M2-pyruvate kinase and S100A12 in severe ulcerative colitis: a prospective multicentre comparison of predicting outcomes and monitoring response Gut 59 2010 1207 1212
28. D. Turner, D. Mack, N. Leleiko, and et al. Severe pediatric ulcerative colitis: a prospective multicenter study of outcomes and predictors of response Gastroenterology 138 2010 2282 2291
29. K.L. Kolho, and D. Turner Fecal calprotectin and clinical disease activity in pediatric ulcerative colitis ISRN Gastroenterol 2013 2013 179024
30. A.M. Schoepfer, C. Beglinger, A. Straumann, and et al. Ulcerative colitis: correlation of the Rachmilewitz endoscopic activity index with fecal calprotectin, clinical activity, C-reactive protein, and blood leukocytes Inflamm Bowel Dis 15 2009 1851 1858
31. M. De Vos, O. Dewit, G. D'Haens, and et al. Fast and sharp decrease in calprotectin predicts remission by infliximab in anti-TNF naive patients with ulcerative colitis J Crohns Colitis 6 2012 557 562
32. G. D'Haens, M. Ferrante, S. Vermeire, and et al. Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease Inflamm Bowel Dis 18 2012 2218 2224
33. A.M. Schoepfer, C. Beglinger, A. Straumann, and et al. Fecal calprotectin more accurately reflects endoscopic activity of ulcerative colitis than the Lichtiger Index, C-reactive protein, platelets, hemoglobin, and blood leukocytes Inflamm Bowel Dis 19 2013 332 341
34. M. Montalto, A. Gallo, L. Santoro, and et al. Role of fecal calprotectin in gastrointestinal disorders Eur Rev Med Pharmacol Sci 17 2013 1569 1582
35. P.F. van Rheenen, E. Van de Vijver, and V. Fidler Faecal calprotectin for screening of patients with suspected inflammatory bowel disease: diagnostic meta-analysis BMJ 341 2010 c3369
36. W.J. Sandborn, B.G. Feagan, C. Marano, and et al. Subcutaneous golimumab induces clinical response and remission in patients with moderate to severe ulcerative colitis Gastroenterology 146 2014 85 95
37. W.J. Sandborn, B.G. Feagan, C. Marano, and et al. Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis Gastroenterology 146 2014 96 109
38. B.G. Feagan, P. Rutgeerts, B.E. Sands, and et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis N Engl J Med 369 2013 699 710